Last reviewed 2026-06-02 · How we verify

EU-approved Neulasta

Pfizer · Phase 1 active Small molecule ✓ Verified Jun 2026

EU-approved Neulasta is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development. Also known as: Pegfilgrastim, Amgen.

Neulasta is used to treat Neutropenia and Acute Myeloid Leukemia, as indicated by ClinicalTrials.gov. Its mechanism of action is not specified in the provided facts, but it is known to be used in conjunction with other treatments such as Bortezomib and Gemtuzumab Ozogamicin.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EU-approved Neulasta
Also known as	Pegfilgrastim, Amgen
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EU-approved Neulasta CI brief — competitive landscape report
EU-approved Neulasta updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about EU-approved Neulasta

What is EU-approved Neulasta?

EU-approved Neulasta is a Small molecule drug developed by Pfizer.

Who makes EU-approved Neulasta?

EU-approved Neulasta is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

Is EU-approved Neulasta also known as anything else?

EU-approved Neulasta is also known as Pegfilgrastim, Amgen.

What development phase is EU-approved Neulasta in?

EU-approved Neulasta is in Phase 1.

Manufacturer: Pfizer — full pipeline
Also known as: Pegfilgrastim, Amgen

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing